Stock Taper
VivoSim Labs, Inc. develops 3D human tissues using proprietary bioprinters for disease modeling and drug testing, with lead candidates in clinical trials for inflammatory bowel disease and liver fibrosis.

NAMkind™ is a preclinical platform using 3D human liver and intestine models to assess drug toxicity, offering a human-relevant alternative to animal testing for early prediction of drug-induced injuries.
| Icon | PRODUCT | Q1-2027 |
|---|---|---|
![]() | Royalty | $18K |
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
XTLB | $2.78 | COMPARE |
CYCN | $3.89 | COMPARE |
KTTA | $0.54 | COMPARE |
PLRZ | $10.30 | COMPARE |
QNRX | $5.57 | COMPARE |
PMCB | $0.53 | COMPARE |
TCRT | $1.76 | COMPARE |
RADX | $2.44 | COMPARE |